Program
AGA2118
A development code.
Its studies are mostly in Osteoporosis, Postmenopausal · Osteoporosis, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Angitia Biopharmaceuticals | 21 open or running | phase 2since Aug 14, 2024 | Jan 11, 2022 | Dec 2026phase 2 · NCT06577935 |
| Angitia | 10 open or running | phase 1since Jan 16, 2026 | Jan 16, 2026 | none ahead |
Also a collaborator on its studies: angitia-australia-pty-ltd.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jan 11, 2022First study: phase 1 study in OsteoporosisNew to Angitia BiopharmaceuticalsAngitia Biopharmaceuticals · NCT05225857 · 90 enrolled · Australia
- Aug 14, 2024Phase 2 study in Osteoporosis, PostmenopausalAngitia Biopharmaceuticals · NCT06577935 · 379 enrolled · United States, Argentina, Poland and more
- Jan 16, 2026Angitia's first study: phase 1 study in Healthy ParticipantsNew to AngitiaAngitia · NCT07361354 · 28 enrolled · United States
Ahead
- Dec 2026Primary completion: phase 2 study in Osteoporosis, PostmenopausalAngitia Biopharmaceuticals · NCT06577935
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07361354Healthy Participants · United States | 1 | Completed | Angitia | Sep 5, 2026 | 28 |
| NCT06577935Osteoporosis, Postmenopausal · United States, Argentina, Poland and more | 2 | Active, not recruiting | Angitia Biopharmaceuticals | Dec 2026 | 379 |
| NCT05225857Osteoporosis · Australia | 1 | Completed | Angitia Biopharmaceuticals | Jan 13, 2024 | 90 |
How it is read
Names in the registry
- “AGA2118”, 3 entries
Codes read as this program: AGA2118.
Conditions, from the studies’ own filings
- Osteoporosis, Postmenopausal, 1 study
- Osteoporosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.